Muse bio today announced the publication of a paper in Nature Biotechnology describing, for the first time, its foundational technology platform that enables rational engineering of the whole genome with single-nucleotide precision. The technology, “CRISPR-enabled trackable genome engineering” (CREATE), has … Continued
Muse bio, a privately-held company leading the development of next-generation genome engineering technologies, today announced that Dr. Kevin Ness has been appointed Chief Executive Officer and member of the Board of Directors. Kevin succeeds Muse bio’s founding CEO Ryan Gill, … Continued
Spark Therapeutics (NASDAQ:ONCE) and Selecta Biosciences, Inc. (NASDAQ:SELB) today announced a license agreement that provides Spark Therapeutics with exclusive worldwide rights to Selecta’s proprietary Synthetic Vaccine Particles (SVP™) platform technology for co-administration with gene therapy targets, including FVIII for hemophilia A, as … Continued
SQZ Biotech announced today an additional $8 million in Series B financing from GV (formerly known as Google Ventures) and Quark Venture Inc. The funding augments an earlier closing of $16 million led by NanoDimension and Polaris Partners in September … Continued
ARMO BioSciences, Inc., a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) Orphan Drug designation for the treatment of pancreatic cancer. The Agency also granted … Continued
Emulate Inc. announced today that its human Lung-Chip system has expanded functionality to now also model conditions in which inhaled toxins enter the lung, including cigarette smoke, e-cigarettes constituents, and potentially environmental airborne contaminants. The new applications are based on … Continued
Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that it has dosed the first patient in its Phase 2 clinical trial of SEL-212, the company’s lead proprietary immunotherapeutic product … Continued